CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.130
+1.202 (129.43%)
At close: May 12, 2025, 4:00 PM
2.170
+0.040 (1.88%)
Pre-market: May 13, 2025, 9:18 AM EDT

CytomX Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
May '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
17281104106283303
Upgrade
Market Cap Growth
-65.51%-22.37%-1.80%-62.58%-6.69%-19.81%
Upgrade
Enterprise Value
100-26-75-70697
Upgrade
Last Close Price
2.131.031.551.604.336.55
Upgrade
PE Ratio
4.392.53----
Upgrade
Forward PE
--16.30---
Upgrade
PS Ratio
1.240.581.031.997.574.43
Upgrade
PB Ratio
7.41-176.77-2.19-1.23-615.53-38.95
Upgrade
P/TBV Ratio
7.29-----
Upgrade
P/FCF Ratio
-----102.63
Upgrade
P/OCF Ratio
-----57.57
Upgrade
EV/Sales Ratio
0.68---1.840.11
Upgrade
EV/FCF Ratio
-----2.48
Upgrade
Debt / Equity Ratio
0.33-20.58-0.29-0.21-47.22-3.20
Upgrade
Debt / EBITDA Ratio
0.200.31----
Upgrade
Debt / FCF Ratio
-----8.43
Upgrade
Asset Turnover
1.040.860.440.180.110.20
Upgrade
Quick Ratio
1.631.211.141.513.934.65
Upgrade
Current Ratio
1.731.251.171.553.994.76
Upgrade
Return on Equity (ROE)
------299.13%
Upgrade
Return on Assets (ROA)
15.87%9.69%-1.75%-19.54%-20.78%-14.38%
Upgrade
Return on Capital (ROIC)
312.36%----378.62%-104.99%
Upgrade
Return on Capital Employed (ROCE)
74.50%71.90%----
Upgrade
Earnings Yield
24.23%39.54%-0.55%-93.93%-41.01%-21.41%
Upgrade
FCF Yield
-47.49%-107.36%-54.78%-106.42%-42.70%0.97%
Upgrade
Buyback Yield / Dilution
-10.23%-14.82%-12.27%-2.48%-39.01%-1.79%
Upgrade
Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q